New findings for glioblastoma presented at AACR

Physician-scientists from University Hospitals (UH) Case Medical Center\'s Seidman Cancer Center and Case Western Reserve University School of Medicine presented new research findings in 24 presentations at the Annual Meeting of the American Association for Cancer Research (AACR) in Chicago, Illinois. \"The breadth and depth of this innovative cancer research presented at AACR is truly outstanding,\" says Stan Gerson, MD, Director of the Seidman Cancer Center at UH Case Medical Center and the Case Comprehensive Cancer Center at Case Western Reserve University. \"Our faculty members are making tremendous advances in hematology and oncology which is reflected in their being chosen for oral and poster presentations.\" Two innovative studies are investigating novel methods that may help clinicians bring a greater specificity to the treatment of glioblastoma (GBM) in the future. GBM is the most common malignant primary brain tumor in adults and also the most aggressive. Median survival time for GBM is approximately 12-15 months. A study led by Jill Barnholtz-Sloan, PhD, Associate Professor at Case Comprehensive Cancer Center and Case Western Reserve University School of Medicine, sought to identify protein biomarkers that can help physicians determine which patients may benefit from standard treatment for GBM. Using research tumor samples from patients with short-term survival (defined as